To the Editor.—
Recent reports have documented prolongation of prothrombin and bleeding times in patients receiving moxalactam disodium.1-3 These reports have resulted in changes in the manufacturer's recommendations so that patients now should receive supplemental vitamin K. It is also recommended that bleeding times be monitored in patients receiving more than 4 g daily. Prolonged bleeding times developed in the cases of three patients receiving "low-dose" moxalactam. One patient experienced clinical bleeding, and a possible additive or synergistic effect of calcium channel-blocking agents is suggested in two of the cases.
Report of Cases.—Case 1.—
A 59-year-old man was treated with moxalactam for a Serratia marcescens bacteremia secondary to a urinary tract infection. His initial serum creatinine value was 2.2 mg/dL, and he received 1 g every 12 hours intravenously (IV) as well as supplemental vitamin K. The azotemia was prerenal, and his creatinine level fell to 1.1
Bach MC. Prolonged Bleeding Time Associated With 'Low-Dose' Moxalactam Therapy. JAMA. 1984;251(23):3082. doi:10.1001/jama.1984.03340470018015
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: